NasdaqGS:UTHRBiotechs
The Bull Case For United Therapeutics (UTHR) Could Change Following Positive TETON-2 Results for Tyvaso in IPF
United Therapeutics recently announced that its phase 3 TETON-2 trial showed nebulized Tyvaso significantly improved lung function for patients with idiopathic pulmonary fibrosis compared to placebo over 52 weeks.
The trial’s positive outcomes were observed across all major patient subgroups, including those on existing therapies, highlighting Tyvaso's potential to fulfill a pressing unmet need in IPF treatment.
We'll explore how the successful TETON-2 results for Tyvaso may expand United...